



**CAI LAY VETERINARY
PHARMACEUTICAL JOINT
STOCK COMPANY**

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

No.: 02/2025/NQ/ĐHĐCĐ-MKV

Tien Giang, April 19, 2025

RESOLUTION
ANNUAL GENERAL MEETING OF SHAREHOLDERS 2025
CAI LAY VETERINARY PHARMACEUTICAL JOINT STOCK COMPANY

Pursuant to:

- The Law on Enterprises No. 59/2020/QH14 dated June 17, 2020;
- The Charter of Cai Lay Veterinary Pharmaceutical Joint Stock Company;
- The Minutes of the Annual General Meeting of Shareholders of Cai Lay Veterinary Pharmaceutical Joint Stock Company dated April 19, 2025;

RESOLVED

Article 1: Approval of the 2024 Report of the Board of Directors.

- Revenue and other income	: 119.558.213.815 VND
- Expenses	: 110.361.653.749 VND
- Profit before tax	: 9.196.560.066 VND
- Corporate income tax	: 2.427.245.295 VND
- Profit after CIT	: 7.324.302.326 VND

This resolution was passed with a unanimous approval rate of 100% of the total voting shares present at the meeting in favor, and will take effect immediately.

Article 2: Approval of the Supervisory Board's Report for the Year 2024

2.1 Business Scale:

As of December 31, 2024, the total enterprise value of the Company was 109,488,706,504 VND (a decrease of 11,162,723,984 VND compared to the beginning of the year). Specifically:

No.	Indicators	Beginning 2024 (01/01/2024)	By the end of 2024 (31/12/2024)
1	Cash and Cash Equivalents	9.191.736.471	15.174.991.167
2	Short-term Financial Investments	6.000.000.000	6.000.000.000
3	Short-term Receivables	33.106.484.040	38.541.119.225
4	Inventories	12.989.882.445	16.641.723.523
5	Other Short-term Assets	654.756.610	629.165.139
6	Long-term Receivables	0	0
7	Fixed Assets	34.359.037.259	30.128.258.708
8	Construction in Progress (Long-term Work in Progress)	0	0
9	Other Long-term Assets	808.526.222	602.901.714
	TOTAL	98.325.982.520	109.488.706.504

2.2 Working Capital of Company

As of December 31, 2024, the Company's regular working capital was 109,488,706,504 VND, including:

- Owner's equity : 87,145,926,069 VND
- Short-term loans : 0 VND
- Long-term loans : 0 VND
- Other capital : 22,342,780,435 VND
(legitimate payables and appropriated funds)

Compared to 2023, regular working capital of the Company decreased by 11.4%, equivalent to a reduction of 11,162,723,984 VND.

2.3 Business Performance in 2024

- Revenue and other income : 119,558,213,815 VND
- Expenses : 110,361,653,749 VND
- Profit before tax : 9,196,560,066 VND
- Corporate income tax expense : 2,427,245,295 VND
- Profit after tax : 7,324,302,326 VND

The profit after CIT for 2024 reached 7,324,302,326 VND, an increase of 1,122,834,424 VND compared to 2023, in which the profit after CIT was 6,201,467,902 VND.

This resolution was adopted with a unanimous approval rate of 100% of the total voting shares present at the meeting and shall take effect immediately.

Article 3: Approval of the Proposal for the Appointment of a New Member to the Board of Directors

Approving the resignation letter from the position of Chairman of the Board of Directors of Cai Lay Veterinary Pharmaceutical Joint Stock Company of Mr. Dao Manh Luong from April 19, 2025.

The General Meeting of Shareholders unanimously approved the resignation of the Chairman of the Board of Directors with a ratio of 100% of the voting shares present at the General Meeting of Shareholders.

Mr. Dao Manh Hoa is hereby appointed as a Member of the Board of Directors of Cai Lay Veterinary Pharmaceutical Joint Stock Company, effective from April 19, 2025.

This resolution was adopted with a unanimous approval rate of 100% of the total voting shares present at the meeting and shall take effect immediately.

Article 4: Approval of the 2025 Business Plan Proposal

The business plan for 2025 is as follows:

DETAILS		Plan for 2025	
		Revenue	Rate
1	Revenue	122.946.000.000	100 %
2	Profit before CIT	8.017.058.375	6,5 %

This resolution was adopted with a unanimous approval rate of 100% of the total voting shares present at the meeting and shall take effect immediately.

Article 5: Approval of the Supervisory Board's Proposal on the Selection of the Auditor for the 2025 Financial Statements

The Supervisory Board of Cai Lay Veterinary Pharmaceutical Joint Stock Company respectfully submits to the 2025 Annual General Meeting of Shareholders for consideration and authorization of the Board of Directors to select an auditing firm for the 2025 financial statements.

005054
ÔNG
PH
CQC TI
CAIL
4Y-T.

This resolution was adopted with a unanimous approval rate of 100% of the total voting shares present at the meeting and shall take effect immediately.

Article 6: Approval of the Proposal on Remuneration for the Board of Directors, Supervisory Board, and Corporate Governance Officer for 2025

The regular expenses for the Board of Directors (BOD), Supervisory Board (SB), and the Corporate Governance Officer (CGO) in 2025 are estimated at 264,000,000 VND (Two hundred sixty-four million VND), accounting for 0.21% of the Company's total revenue, including:

- Remuneration for BOD, SB, and CGO : 144,000,000 VND
- Management and bonus expenses : 120,000,000 VND

Remuneration of the Board of Directors, Board of Supervisors and Company Administrators in 2025 is as follows:

- Chairman of the BOD : 3,000,000 VND /month
- Member of the BOD : 2,000,000 VND /month
- Head of the Supervisory Board : 2,000,000 VND /month
- Member of the Supervisory Board : 1,000,000 VND /month
- Corporate Governance Officer : 1,000,000 VND /month

To ensure flexibility in operations, the Board of Directors proposes that the General Meeting of Shareholders authorize the Chairman of the Board to approve the specific remuneration for individual members of the Board of Directors, in cases where such members are directly involved in activities that promote the Company's business operations, provided that the interests of shareholders and the Company are ensured.

Article 7: Approval of the dividend payment report in 2024

The General Meeting unanimously disapproved the content of the above report with the rate of 99.9% of the voting shares present at the General Meeting.

Article 8: Implementation Provisions

The General Meeting of Shareholders authorizes the Board of Directors to organize and implement the contents approved by the General Meeting, ensuring the interests of both shareholders and the Company, and in compliance with applicable laws and the Company's Charter.

This resolution was adopted with a unanimous approval rate of 100% of the total voting shares present at the meeting and shall take effect immediately.

The General Meeting of Shareholders unanimously assigns the Board of Directors and the Supervisory Board to implement this Resolution, which was approved at the Annual General Meeting on April 19, 2025, and to report to the General Meeting of Shareholders at subsequent meetings.

The full text of this Resolution was approved by the General Meeting of Shareholders with a unanimous approval rate of 100% of the total voting shares present at the meeting and shall take effect from April 19, 2025.

Received:

- Shareholders
- Hanoi Stock Exchange (HNX)
- Board of Directors (BOD)
- Supervisory Board (SB)
- Executive Board
- Archive: Administration Department

**ONBEHALF OF BOARD OF DIRECTORS
MEMBER OF THE BOARD OF DIRECTOR**



Nguyen Anh Tuan